Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RVT 2001

Next Previous
Search
Drug Profile

RVT 2001

Alternative Names: H3B-8800; RVT-2001

Latest Information Update: 27 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator H3 Biomedicine
  • Developer Eisai Inc; H3 Biomedicine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action SF3B1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Chronic myelomonocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 07 Dec 2024 Pharmacodynamics data from preclinical study presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 13 Feb 2024 Discontinued - Phase-I for Acute myeloid leukaemia in Taiwan, South Korea, Italy, Belgium, Germany, Spain, France, USA (PO)
  • 13 Feb 2024 Discontinued - Phase-I for Chronic myelomonocytic leukaemia in Taiwan, South Korea, Italy, Belgium, Germany, Spain, USA, France (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top